Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
Nimbus Therapeutics
company
About
Nimbus Therapeutics uses computational technology to create selective small molecule therapeutics.
- Cambridge,Massachusetts,United States
- 101 - 250
- http://nimbustx.com
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- $125M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 2009
- Number Of Employee
- 101 - 250
- Operating Status
- Active
- Legal Name
- Nimbus Therapeutics, Inc.
- Also Known As
- Nimbus Discovery
Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical-stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. Nimbus Therapeutics designs highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer, and immune-inflammatory disorders.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
8
$427M
Nimbus Therapeutics has raised a total of
$427M
in funding over 2 rounds. Their latest funding was raised on
Sep 12, 2022 from a Series Unknown round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 12, 2022 | Series Unknown | $125M | 10 | — | — | Detail |
| Jul 13, 2021 | Series Unknown | $105M | 7 |
Biotechnology Value Fund
|
— | Detail |
| Oct 14, 2020 | Series Unknown | $60M | 2 | — | — | Detail |
| Jun 5, 2018 | Series C | $65M | 7 |
SR One
|
— | Detail |
| Mar 19, 2015 | Series B | $43M | 6 |
Pfizer Venture Investments
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
7
17
Nimbus Therapeutics is funded by 17 investors.
Access Biotechnology
and Atlas Venture
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Access Biotechnology
|
— | Series Unknown |
Atlas Venture
|
— | Series Unknown |
Bain Capital Life Sciences
|
— | Series Unknown |
Bill Gates
|
— | Series Unknown |
|
Biotechnology Value Fund
|
— | Series Unknown |
|
|
— | Series Unknown |
|
Pfizer Venture Investments
|
— | Series Unknown |
RA Capital Management
|
— | Series Unknown |
|
SR One
|
— | Series Unknown |
SV Health Investors
|
— | Series Unknown |
Employee Profiles
Number of Employee Profiles
16
Nimbus Therapeutics has 16 current employee profiles, including
Executive Bruce Booth
Executive
Board member
Board member
Executive
Board member
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
